A new once-a-day eye drop that works differently from other glaucoma drugs is opening a new horizon in treatment of the disease.
“For the first time, we have a drug which directly addresses specific anatomical and physiological changes that cause pressure rise and works at the level of the pathology rather than just on IOP alone,” Inder Paul Singh, MD, told Ocular Surgery News.
The Rho kinase inhibitor Rhopressa (netarsudil ophthalmic solution 0.02%, Aerie Pharmaceuticals) was approved in the United States following three pivotal phase 3 registration trials, Rocket 1, (Read more...)
Uncategorized